FDAsafety guidance83% confidence
Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to nontuberculous mycobacterial lung disease patients.
Regulatory Analysis
As part of the Accelerating Rare disease Cures (ARC) Program, CDER’s Rare Diseases Team inaugurated the Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D) initiative. Learn more.
Supporting Context
- Therapeutic area
- Pulmonology · Nontuberculous Mycobacterial Lung Disease
- Sub-indication
- General
Related signal: Inhaled 3% hypertonic saline shows promise for antibiotic-naïve NTM lung disease